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Dear Prof. Martin Kolb, Editor in Chief
Dear Prof. James D. Chalmers, Deputy Editor
Dear Prof. Joachim Muller-Quernheim, Associate Editor
European Respiratory Journal
Thank you very much indeed for giving us the opportunity to submit a revised version of our 
manuscript “Clinical differences in sarcoidosis patients with and without lymphoma: a single-center 
retrospective cohort analysis” (Manuscript ID ERJ-02470-2018). We have addressed all the points 
very reasonably raised by the Reviewers and amended our manuscript accordingly. We believe this 
has increased considerably the quality of our article.
Please find below a point-by-point reply to the Reviewers and Associate Editor comments, as 
requested.
We hope our revised manuscript will be considered for publication in the European Respiratory 
Journal in its present form
Sincerely yours
Fabrizio Luppi (for the Authors)































































ACE measurement is not standardized. Cut-off values vary from laboratory to laboratory. Please 
check whether your lab kept the system constant over the observation time.
AE.R1
We thank the Associate Editor for this insightful and reasonable comment. All of the angiotensin-
converting enzyme (ACE) assays have been performed in the laboratory of our University Hospital, 
which provides certified and standardized analysis and is a referral center for the entire county (i.e., 
approximately 1 million people population). Specifically, the methodology of ACE measurement has 
remained the same throughout the study period, and certified internal as well as external quality 
control has been regularly performed over time. Therefore, we confirm that ACE measurements 
have been performed using a consistent methodology and have provided highly reliable values.
AE.C2
You mention a correlation between BAL cytology CD4/CD8 ratio and lymphoma. This of practical 
interest since BAL is done quite frequently in Europe. Please give some more details.
AE.R2
We agree with the Associate Editor that the correlation between BAL CD4/CD8 and lymphoma, if 
confirmed, could potentially be important and clinically relevant. However, in our study, BAL was 
performed in only 5 out of 10 patients affected by sarcoidosis and lymphoma. Although an increased 
CD4/CD8 ratio was observed in the BAL fluid of all 5 patients, we decided not to include these data 
due to the limited number of patients and the possibility that these may represent spurious results. 
We hope the Associate Editor agrees with this decision.
Reviewer 1
R1.C1
In the methods, the authors state that comparisons were performed with the two-samples Student´s 
T test, assuming equal variance for all the variables tested in the 2 groups. Variance should be tested, 
and a non-parametric test should be used when appropriate. Furthermore, the authors compare also 
categorical variables, and other tests should be used to compare these variables in the 2 groups. 
Please clarify and adjust the analysis as requested
R1.R1
We thank the Reviewer for his/her comment. T test was used in variables assumed to be normally 
distributed and for which the assumption of equal variances was not rejected. This has now been 
clarified. Please, see text for details.
R1.C2
The authors state that the occurrence of lymphoma is usually considered more frequent among cases 
of chronic sarcoidosis; however, 50% of sarcoidosis-lymphoma in their cohort presented with a stage 
I, and no patients with sarcoidosis-lymphoma experienced a relapse of sarcoidosis. These facts raise 
2 concerns: 1) the sequence of the events: the authors do not differentiate cases presenting first with 
lymphoma and subsequently developing sarcoidosis and vice versa; please provide this information; 
2) which where the diagnostic criteria to diagnose sarcoidosis and lymphoma in these cases? Did the 





























































patients undergo EBUS or surgical biopsies of the nodes to verify both the diseases? Was the 
diagnosis of sarcoidosis based on BAL and clinical-radiological features alone? Was the diagnosis of 
lymphoma based on biopsies from organs other than the lung/mediastinal nodes?
R1.R2
This is a crucial point and we thank the Reviewer for raising it. As he/she points out, most cases of 
lymphoma tend to occur in chronic sarcoidosis, which was not the case in our study population.
With regard to the two specific points raised:
1. Five out of ten patients affected by sarcoidosis subsequently developed lymphoma. 
Conversely, in the remaining five cases, lymphoma preceded sarcoidosis.
2. In 183 patients enrolled in our study, the diagnosis of sarcoidosis was based on a compatible 
clinical radiological picture, histological evidence of noncaseating granulomatous 
inflammation and after careful exclusion of other diseases that may present with a similar 
clinical, radiological, or histological features. In the remaining 26 cases, the diagnosis was 
based on a compatible clinical and/or radiological picture, as occurred in patients presenting 
with Lofgren’s syndrome, BAL cell count and CD4/CD8 ratio >3.5 and/or nuclear medicine 
data, after careful exclusion of alternative diagnoses. The diagnosis of lymphoma was always 
confirmed histologically, performing skin (two patients), bone marrow (four patients) and 
lymph node biopsy in various sites, such as abdomen (one patient), latero-cervical area (two 
patients) and mediastinoscopy (one patient).
R1.C3
Length of the follow-up and survival: the authors state that there was no difference in survival 
between the 2 groups; on the other hand, they report only data on the follow-up time at their centre; 
was the survival obtained from a death registry or the comparison is performed using the follow-up 
time? Please clarify.    
R1.R3
We thank the Reviewer for this comment. The death/survival status of all patients included in the 
study was obtained from a death registry that is linked to a software utilized in our University 




It will be useful to have more detailed information about the SA diagnosis (how many patients 
performed a BAL/biopsy?), the kind of lymphoma, clinical onset of SA and LY.
R2.R1
We thank the Reviewer for this comment, which mirrors one of Reviewer’s 1 comments. As already 
clarified, in 183 patients enrolled in the study, the diagnosis of sarcoidosis was formulated based on 
a compatible clinical and/or radiological picture, histological evidence of noncaseating granulomas 
and exclusion of other diseases able to present with a similar histological or clinical picture. In the 
remaining 26 patients, the diagnosis was based on a compatible clinical and/or radiological picture, 
as is the case in patients affected by Lofgren’s syndrome, on BAL cellular count together with an 





























































increased CD4/CD8 ratio and/or nuclear medicine investigations, as well as on the exclusion of other 
diseases able to present with a similar histological or clinical picture.
Regarding the type of lymphoma (10 cases) observed in our series, they were as follows:
o Two diffuse large B-cell lymphomas
o Four follicular lymphomas
o One Hodgkin lymphoma
o One Burkitt’s lymphoma
o One lymphoplasmacytic lymphoma (also known as Waldenstrom’s disease)
o One anaplastic large cell lymphoma
Regarding the clinical onset of sarcoidosis, 31 patients were diagnosed incidentally, 105 patients 
were affected by respiratory symptoms, mainly dry cough and dyspnea either at rest or on exertion, 
42 patients were diagnosed because of systemic symptoms, including fever, malaise, fatigue, weight 
loss and sweats, while 31 patients showed extrapulmonary manifestations, including abdominal 
pain, cutaneous lesions, neurological symptoms and ear, nose and throat manifestations. 
Regarding the clinical onset of lymphoma, the presentation was the following: 
o Diffuse large B-cell lymphomas (n=2): in one patient, during follow-up for his sarcoidosis, 
enlarged mediastinal lymph nodes were detected during steroid treatment. The patient 
underwent mediastinoscopy that allowed the diagnosis of lymphoma to be made; in the 
second patient the diagnosis of lymphoma was made following the occurrence of 
thrombocytopenia and fever.
o Follicular lymphomas (n=4): one patient developed a thoracic consolidation, 
subsequently diagnosed as lymphoma; two patients developed enlarged lymph-nodes 
(latero-cervical and inguinal). In the fourth patient, lymphoma presented as 
subcutaneous mass.
o Hodgkin lymphoma (n=1): the patient complained of systemic symptoms, such as fever, 
malaise and weight loss.
o Burkitt’s lymphoma (n=1): the patient developed a submandibular mass.
o Lymphoplasmacytic lymphoma (also known as Waldenstrom disease) (n=1): the 
diagnosis was made following the occurrence of monoclonal gammopathy (IgM)
o Anaplastic large cell lymphoma (n=1): the patient developed severe leukopenia and 
sepsis.
R2.C2
The X-ray staging is referred to the time of diagnosis of SA or at the time of LY diagnosis? This point 
is unclear and appears to be crucial for this study. Accepting that the lung staging was made at the 
time of SA diagnosis, it is possible to describe a trend of less severe presentation in SA-LY (but not 
with statistical significance). For this reason it could be useful to know the staging at the time of LY 
onset. It can result similar, considering the longer FU for SA-LY group. Or as an alternative, the lung 
involvement can be less severe. In this latter case, the LY treatment could have stopped/slowed down 
the lung damage. Please, clarify and discuss about this.
R2.R2





























































We thank the Reviewer for his/her comment. In our study, the X-ray stage was collected at the time 
of the diagnosis of sarcoidosis. Regarding the radiographic staging at the time of lymphoma 
diagnosis (5 cases) - with the exception of one patient whose X-ray stage worsened – in all other 
cases the radiographic stage at the time of the diagnosis of lymphoma was the same as that 
observed at the time of sarcoidosis diagnosis. Therefore, we are not in a position to speculate on 
the potential association between improved/worsened radiographic stage of disease and 
development of lymphoma.
R2.C3
The value of ACE: Regarding the first determination of ACE levels, these were evaluated at the time 
of the diagnosis of SA, but how many patients in the SA-LY group had already both the disease 
together at the diagnosis? Regarding the second determination, it was reported an unclear “last 
follow up” with a mean difference of about 3 years in the FU between the two groups. So, the second 
determination should be corrected for the disease duration. Furthermore, have you tried to perform 
a ROC curve for ACE to describe a reasonable cut off in terms of sensitivity, specificity and accuracy 
between the two groups? Have you available the ACE levels temporally close to the diagnosis of LY? 
R2.R3
We thank the Referee for these comments. Five patients (corresponding to 50% of those affected 
by both sarcoidosis and lymphoma) developed the two diseases simultaneously. 
In our opinion, the statistically significant increase in serum ACE levels in patients with both 
sarcoidosis and lymphoma suggests that serum ACE might potentially represent a clinical marker at 
the time of the diagnosis. We agree with the Reviewer that the meaning of the measurement 
performed “at the last follow up” is less clear, particularly given the lack of serum ACE data 
temporally close to the diagnosis of lymphoma. Yet, persistently elevated serum ACE levels at the 
second measurement, performed in the same laboratory in both groups at the time of the diagnosis 
and at the last follow-up, support our argument that serum ACE levels may represent a risk factor 
for the development of lymphoma in patients with sarcoidosis, whereas it does not seem to predict 
response to treatment in patients with lymphoma.
R2.C4
Considering the retrospective nature of the work and the large amount of data (mainly regarding 
the organ involvement), a clear quantification of the missing data is needed
R2.R4
As suggested, please find below a detailed list of missing data in our study: 
Smoking habit: 173/209 (82%): missing data 18%
Serum ACE data were available for 161/209 patients (77%): missing data 23%
Lung function tests were available for 157/209 patients (75%): missing data 25%
Radiological imaging data were available for 193/209 patients (93%): missing data 7%
Clinical symptoms were known for 152/209 patients (73%): missing data 27%
Pathology data for sarcoidosis diagnosis were available for 183/209 patients (88% - missing data 
12%), while pathology data were available for 10/10 patients with lymphoma (100%): no missing 
data
R2.C5





























































Page 5 line 14: please, check reference. You wrote about ACE as a biological marker of disease 
progression during follow up citing ref 12 (Miyoshi s et al Chest 2010): in this work ACE NOT 
correlated with BALF regarding total cells, lymphocytes, CD4+ or CD4/CD8 ratio, no difference 
between SA with and without parenchymal infiltration regarding ACE, AUC of only 0.61. In reference 
13 the macrophages rather than CD4+ cells are supposed as the cell source of ACE. Furthermore, ACE 
levels seem to be related with an acute onset of the disease rather than a chronic involvement 
(10.12659/PJR.897708). 
R2.R5
The Reviewer is correct. The references he/she is alluding to are misplaced here or at least they do 
not support the statements they refer to. Accordingly, we have removed them from the reference 
list. 
R2.C6
Page 5 line 15: If the principal sources of ACE are the lung endothelium and the macrophages, I have 
some difficult to explain why LY alone should have less serum ACE level than the control group (ref 
15 you cited), SA alone higher levels than the control group (ref 13 you cited) and your SA-LY group 
higher level respect to SA alone. Lymphocytic activation during LY is reduced? In this case, why SA-
LY have higher levels than SA? This point should be discussed.
R2.R6
We thank the Reviewer for this comment. The mechanisms by which SA-LY patients have higher 
levels of ACE can only be speculated upon. One possibility is that the degree of lymphocytic 
activation of sarcoidosis might differ from the aberrant lymphocytic proliferation that occurs in 
lymphomas. In sarcoidosis, granuloma formation appears to be driven by alveolar macrophages that 
recruit Th-lymphocytes thus triggering a vicious circle in which lymphocytes promote granuloma 
formation and maintenance through the production of cytokines and stimulation and recruitment 
of macrophages and B-cells. In other words, macrophages, that are the main source of ACE, at the 
same time stimulate lymphocytes and are stimulated by the lymphocytes themselves. In this 
scenario, ACE levels could reflect an exaggerated stimulation and activity of lymphocytes. On the 
other hand, the reduced T-reg activity found in sarcoidosis but not in lymphoma might contribute 
to their neoplastic transformation in patients in whom lymphoma occurs after sarcoidosis. More 
studies are needed to clarify the association, if any, between serum ACE levels and lymphoma 
development. 
Minor comments
Page 3 line 7: it can be useful to produce a definition of disease activity for SA. 
Thank you. We have now clarified that in sarcoidosis, the term “disease activity” refers to the fact 
that the disease is still active and may undergo clinical, radiological or functional change as a 
consequence of the persistence of the inciting antigen, which remains unknown. 
Page 3 lines 27-28: p=0.344 is very far from a statistical significance.  No gender differences in SA-LY 
syndrome.
We thank the Reviewer for this comment. While traditionally a preponderance of female patients 
has been reported in sarcoidosis, more recent data suggest this may not be necessarily the case. In 
our study, sarcoidosis was more frequent among females whereas combined sarcoidosis and 





























































lymphoma was more common in males, although this difference only mildly trended towards 
statistical significance. The small number of individuals in our study, however, does not allow us to 
draw firm conclusions. 
Page 4 line 3: please, define “relapse” in sarcoidosis
We thank again the Reviewer for the comment. According to the definition given by Baughman et 
al. (Eur Respir J 2014), which we favor, the term relapse (or exacerbation) of sarcoidosis refers to: 
1) Significant increase in systemic medication; 2) Worsening of chest imaging; 3) Worsening of 
pulmonary function status; 4) Worsening of dyspnea. The presence of any one or more of these 
features is considered progression of the disease.
Page 4 lines 12-14: No statistical difference between the severity of lung involvement between the 
two groups, a trend of significance in FVC liters but not in FVC% predicted. Please, reformulate and 
discuss why in your opinion only FVC liters differ from the two group but not FVC% predicted
We agree with the Reviewer that these inconsistent data may look a bit odd. However, we believe 
the differences between absolute FVC expressed in liters and FVC % predicted may be accounted 
for by the retrospective nature of our study, wherein different spirometers were used over a period 
of time of about 20 years.
Page 5 line 18: a higher CD4/CD8 ratio in SA-LY cohort appears to be a very interesting data. Why it 
was not reported?
Thank you. As already clarified in our response to the AE, we did not report these data because BAL 
was performed only in 5 out of 10 patients with both sarcoidosis and lymphoma. However, we are 
ready to reconsider this decision if the Referee believes these data may provide meaningful 
information.
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Sarcoidosis is a systemic disease of unknown origin, characterized by the presence of non-
caseating granulomas at disease sites1. A relevant clinical problem in the management of this 
disease is the co-existence of other clinical conditions, such as solid tumors or lymphomas, that may 
occur before or following the diagnosis of sarcoidosis as well as simultaneously2. Particularly, the 
association of sarcoidosis and lymphoma is well established and was named the “sarcoidosis-
lymphoma syndrome” by Brincker and colleagues in 19863. In this syndrome, lymphoma occurs 
mainly in patients with a chronic active form of sarcoidosis, suggesting that chronic disease could 
be a risk factor for lymphoma. However, the distinctive clinical features of patients with sarcoidosis 
and lymphoma, and the precise mechanism underlying this association are stillremain unclear.
We retrospectively reviewed the database of the “Center for Rare Lung Diseases” at the 
University Hospital of Modena to identify all subjects with a diagnosis of sarcoidosis between 1990 
and 2013, with the aim to evaluate clinical, functional and serological differences related to the 
presence of lymphoma in sarcoidosis patients, as well as differences in survival. 
We recorded the following clinical data set: gender, age, radiographic (i.e., Scadding) disease 
staging, organ involvement and treatment of both conditions, stage of lymphoma, sarcoidosis and 
lymphoma relapses, pulmonary function tests (PFTs), serology and haematology data as well as 
serum angiotensin-converting enzyme (ACE) levels at the time of diagnosis. These parameters were 
compared between the two groups of patients with andor without lymphoma (see in Table 1). 
We retrieved 209 sarcoidosis patients and found 10 cases (4,8%) with a previous or subsequent 
diagnosis of lymphoproliferative disorder and a mean follow-up of 6.7 years and 9.5 years, 
respectively. 
Differences between groups were tested with a two-sample Student’s T test in continuous 
variables normally distributed with equal variances. The Chi-squared test was used to compare the 
distribution of categorical variables between the two groups, and the Fisher exact test when 
appropriate. Survival was estimated using the Kaplan-Meier method and compared between groups 
with the log-rank test.
Differences between groups were tested with a two-sample Student’s T test assuming equal 
variance between groups, whereas group survival was estimated using the Kaplan-Meier method 
with the log-rank test. 
There was no difference in patients’ median age between the sarcoidosis and the 
sarcoidosis-lymphoma syndrome group (48.7 vs 46 years, p=0.578); the majority of subjects within 





























































the sarcoidosis group were females; in contrast, a slightly, not significant male predominance was 
observed in the sarcoidosis-lymphoma syndrome group (p=0.344).
Most of the patients in the two groups were non-smokers (60.7% and 85.7% in the 
sarcoidosis and sarcoidosis-lymphoma groups, respectively). A difference was found in terms of 
chest X-ray staging, specifically a lower prevalence of respiratory involvementmilder disease 
extent/severity in patients with lymphoma. In fact, stage II was the most common stage in the 
sarcoidosis group, whilst stage I was more frequently represented observed in the sarcoidosis-
lymphoma syndromegroup. PFTs trended towards worsening in the sarcoidosis group, wherein 
functional abnormalities were more likely to be present, although this difference did not reach 
statistical significance a pulmonary involvement was markedly more likely (FVC: 3,3 vs 4,2 liters, 
p=0.052). In addition, 36 relapses (18,9%) of sarcoidosis were reported in the sarcoidosis group, 
while no relapse was observed in the sarcoidosis-lymphoma group. 
We also detected a statistically significant difference in ACE serum levels between groups. 
Indeed, in the sarcoidosis-lymphoma syndrome group, serum ACE level was significantly higher 
compared to patients without lymphoma, both at the time of the diagnosis of sarcoidosis (94.9 UI/L 
vs 55.8 UI/L, p = 0.02) and at the last measurement available (83.3 UI/L vs 50.7 UI/L, p = 0.047). 
FinallyHowever, survival did not differ between the two groups (log-rank test p=0.3724).
In the present study, we investigated whether serological, clinical, functional or radiological 
features may help differentiate patients with sarcoidosis from those with sarcoidosis-lymphoma 
syndrome. We showed that lung involvement as assessed by chest X-ray (Scadding radiographic 
stage II),  and a restrictive ventilatory defect and a higher rate of relapse were more commonly 
associated withamong patients with sarcoidosis alone. (radiological stage II), also showing a 
markedly higher rate of disease relapse. Furthermore, and perhaps more importantlyinterestingly, 
serum ACE levels wereas higher in patients with sarcoidosis-lymphoma syndrome both at the time 
of the diagnosis and at the last follow-up measurement available, indicating that those patients with 
persistently elevated serum ACE levels should probably be carefully monitored over longer periods, 
despite the similar outcomes in term of mortality observed between in the two groups.
Previous epidemiological studies showed an increased incidence of various types of cancers in 
patients with sarcoidosis4. Although , but this association does not seem to be cancer-specific. 
However, breast and testicular tumors are more frequently described in association with 
sarcoidosis5, and may occur either before, concurrently or after onset of sarcoidosis2,6. 
IFurthermore, in patients with either hematological malignancies or solid tumors,  who do not fulfill 





























































the criteria for systemic sarcoidosis, granulomatous inflammation may be found as a “sarcoid 
reaction”, that is a usually frequent findingobserved mainly in the local lymph nodes draining the 
cancer site7. However, these “sarcoid-like reactions” have limited clinical relevance and should not 
be regarded as sarcoidosis. 
Coexistence of sarcoidosis and lymphoma has been reported previouslyis well known. 
Indeed, patients with sarcoidosis are up to 11 times more likely to develop lymphoma as compared 
to the general population8. Specifically, an increased risk of Hodgkin lymphoma was observed in 
patients with sarcoidosis in a population-based case-control study in Scandinavia4. In the majority 
of cases, lymphoma occurred after sarcoidosis, usually within a short time interval of time9. P
The evidence also suggests that patients with sarcoidosis-lymphoma syndrome are generallytend to 
be significantly older than unselected individuals with sarcoidosis10. In contrast, in our study, no 
differences were observed in the median age of patients with or without lymphoma. Different 
genetic background or environmental exposures may account for this controversial inconsistent 
finding1. 
Similarly to our study, Blank and colleagues11 performed a retrospective study analyzing the 
incidence and the type of malignancies in a large cohort of patients with sarcoidosis, showing a 
similar rate of lymphoproliferative disorders (4.1% vs 4.8 % in our study), thus confirming the 
generalizability of our findings.
In our study, a number of limitations should also be acknowledged, tThe main limitations 
ofbeing the present study is the small sample number of patients with sarcoidosis-lymphoma 
syndrome included, although, reassuringly, a comparable rate prevalence of sarcoidosis-lymphoma 
syndrome was found in previous similar studiesobservations of patients with sarcoidosis11. 
Moreover, the retrospective design is prone to incomplete or missing data. Finally, the lack of a 
control population without sarcoidosis followed for over the same period of time precludes us from 
identifying sarcoidosis as a risk factor for malignancy. These limitations n
Notwithstanding, our data suggest that in patients with sarcoidosis persistently elevated serum 
ACE levels could be important in evaluating the should raise the suspicion of supervening risk to 
develop lymphoma in patients with sarcoidosis.  Indeed, ACE is generally even more used as a 
biological marker of disease progressionto monitor disease behaviour during follow-up1, 12, 13.  Thus, 
we might argue speculate that serum ACE levels may reflect the intensity of the lymphocytic 
activation occurring in patients with sarcoidosis, and that an exuberant and uncontrolled 
lymphocytic activation, perhaps not counterbalanced by T-regulatory cell activity12, may trigger 





























































predispose to an increased risk forthe development of  lymphoma development. In support of our 
hypothesis, eEvidence suggests that serum ACE is lower in malignant patients with lymphoma 
alone135. As a side observation, we iInterestingly, we also observed that the CD4/CD8 lymphocyte 
ratio in bronco-alveolar lavage was higher among patients with sarcoidosis-lymphoma syndrome 
(data not shown), further supporting the hypothesis of an aberrant lymphocytic activation (T-
helper) in patients with both conditions.
In conclusion, our study suggests the existence of clinical, radiological and serological 
differences in sarcoidosis with or without lymphoma syndrome. The knowledge of these differences 
seems important for a timely diagnosis and treatment. However, furtherLarger prospective studies 
are required to confirm present and expand on these observations.
We acknowledge that this research was partially supported by the Italian Ministry of University and 
Research (MIUR) - Department of Excellence project PREMIA (PREcision MedIcine Approach: 
bringing biomarker research  to clinic)  





























































Table 1. Demographic and clinical characteristics of the study population
Sarcoidosis Sarcoidosis + Lymphoma P
Patients, n 199 10
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             Ex








FVC, litres 3.3 (± 1,1) 4.2 (± 0,8) 0.052
FVC, % predicted 96.2 (± 18.0) 100.1 (± 19,2) 0.583
FEV1, litres 2.7 (± 0,9) 3.3 (± 0,6) 0.92
FEV1, % predicted 94.4 (± 19,1) 97.1 (± 18.0) 0.720
DLCO, ml min kPa 6.2 (± 2,6) 7.4 (± 1,8) 0.234
DLCO, % predicted 73.9 (± 23,8) 75.3 (± 15,3) 0.881
Chest X-rays stage (%)
Stage 0 15 (7.5) 0 (0)
Stage 1 59 (29.7) 5 (50)
Stage II 89 (44.7) 3 (30) 0.671
Stage III 30 (15.1) 2 (20)
Stage IV 6 (3.0) 0 (0)
ACE (U/L)
At diagnosis 55.1 (± 36,7) 94.9 (± 43,9) 0.02
First relapse 86.0 (± 56,4) - N/A
Last follow up 50.7 (± 41,7) 83.3 (± 42,5) 0.04
Relapses 36 (18.9%) 0 (0%) N/A
Organ involvement
Mediastinum 159 (79.9) 8 (80) 0.994
Lungs 137 (68.8) 7 (70) 0.939
Skin 53 (26.6) 4 (40) 0.354
Lymph-nodes 34 (17.6) 3 (30) 0.321
Eyes 12 (6.0) 1 (10) 0.612
Spleen 12 (6.0) 1 (10) 0.612
Liver 17 (8.5) 0 (0) 0.335
Salivary glands 5 (2.5) 0 (0) 0.999
Nervous system 7 (3.5) 0 (0) 0.999
Hypercalcemia 1 (0.5) 0 (0) 0.999
Bones 2 (1.0) 1 (10) 0.137
ORL 1 (0.5) 0 (0) 0.999
Gastrointestinal 2 (1.0) 0 (0) 0.999
Lacrimal glands 1 (0.5) 1 (10) 0.094
Bone marrow 2 (1.0) 0 (0) 0.999
Heart 1 (0.5) 0 (0) 0.999
Testis 1 (0.5) 0 (0) 0.999





























































Continuous variables are expressed as mean±SD if normally distributed, as median (min, max) if non-normally distributed; 
categorical variables are expressed as absolute numbers and percentages
N/A = not applicable
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Sarcoidosis is a systemic disease of unknown origin, characterized by the presence of non-
caseating granulomas at disease sites1. A relevant clinical problem in the management of this 
disease is the co-existence of other clinical conditions, such as solid tumors or lymphomas, that may 
occur before or following the diagnosis of sarcoidosis as well as simultaneously2. Particularly, the 
association of sarcoidosis and lymphoma is well established and was named the “sarcoidosis-
lymphoma syndrome” by Brincker and colleagues in 19863. In this syndrome, lymphoma occurs 
mainly in patients with a chronic active form of sarcoidosis, suggesting that chronic disease could 
be a risk factor for lymphoma. However, the distinctive clinical features of patients with sarcoidosis 
and lymphoma, and the precise mechanism underlying this association remain unclear.
We retrospectively reviewed the database of the “Center for Rare Lung Diseases” at the 
University Hospital of Modena to identify all subjects with a diagnosis of sarcoidosis between 1990 
and 2013, with the aim to evaluate clinical, functional and serological differences related to the 
presence of lymphoma in sarcoidosis patients, as well as differences in survival. 
We recorded the following clinical data: gender, age, radiographic (i.e., Scadding) disease 
staging, organ involvement and treatment of both conditions, stage of lymphoma, sarcoidosis and 
lymphoma relapses, pulmonary function tests (PFTs), serology and haematology data as well as 
serum angiotensin-converting enzyme (ACE) levels at the time of diagnosis. These parameters were 
compared between patients with and without lymphoma (Table 1). 
We retrieved 209 sarcoidosis patients and found 10 cases (4,8%) with a previous or subsequent 
diagnosis of lymphoproliferative disorder and a mean follow-up of 6.7 years and 9.5 years, 
respectively. 
Differences between groups were tested with a two-sample Student’s T test in continuous 
variables normally distributed with equal variances. The Chi-squared test was used to compare the 
distribution of categorical variables between the two groups, and the Fisher exact test when 
appropriate. Survival was estimated using the Kaplan-Meier method and compared between groups 
with the log-rank test.
There was no difference in patients’ median age between the sarcoidosis and the 
sarcoidosis-lymphoma syndrome group (48.7 vs 46 years, p=0.578); the majority of subjects within 
the sarcoidosis group were females; in contrast, a slightly, not significant male predominance was 
observed in the sarcoidosis-lymphoma syndrome group (p=0.344).
Most of the patients in the two groups were non-smokers (60.7% and 85.7% in the 
sarcoidosis and sarcoidosis-lymphoma groups, respectively). A difference was found in terms of 





























































chest X-ray staging, specifically a milder disease extent/severity in patients with lymphoma. In fact, 
stage II was the most common stage in the sarcoidosis group, whilst stage I was more frequently 
observed in the sarcoidosis-lymphoma group. PFTs trended towards worsening in the sarcoidosis 
group, wherein functional abnormalities were more likely to be present, although this difference 
did not reach statistical significance (FVC: 3,3 vs 4,2 liters, p=0.052). In addition, 36 relapses (18,9%) 
of sarcoidosis were reported in the sarcoidosis group, while no relapse was observed in the 
sarcoidosis-lymphoma group. 
We also detected a statistically significant difference in ACE serum levels between groups. 
Indeed, in the sarcoidosis-lymphoma syndrome group, serum ACE level was significantly higher 
compared to patients without lymphoma, both at the time of the diagnosis of sarcoidosis (94.9 UI/L 
vs 55.8 UI/L, p = 0.02) and at the last measurement available (83.3 UI/L vs 50.7 UI/L, p = 0.047). 
However, survival did not differ between the two groups (log-rank test p=0.3724).
In the present study, we investigated whether serological, clinical, functional or radiological 
features may help differentiate patients with sarcoidosis from those with sarcoidosis-lymphoma 
syndrome. We showed that lung involvement as assessed by chest X-ray (Scadding radiographic 
stage II), a restrictive ventilatory defect and a higher rate of relapse were more common among 
patients with sarcoidosis alone. Furthermore, and perhaps more interestingly, serum ACE levels 
were higher in patients with sarcoidosis-lymphoma syndrome both at the time of the diagnosis and 
at the last follow-up measurement available, indicating that patients with persistently elevated 
serum ACE levels should probably be carefully monitored over longer periods, despite the similar 
outcomes in term of mortality observed in the two groups.
Previous epidemiological studies showed an increased incidence of various types of cancers in 
patients with sarcoidosis4, but this association does not seem to be cancer-specific. However, breast 
and testicular tumors are more frequently described in association with sarcoidosis5, and may occur 
either before, concurrently or after onset of sarcoidosis2,6. In patients with either hematological 
malignancies or solid tumors, granulomatous inflammation is a frequent finding mainly in the local 
lymph nodes draining the cancer site7. However, these “sarcoid-like reactions” have limited clinical 
relevance and should not be regarded as sarcoidosis. 
Coexistence of sarcoidosis and lymphoma is well known. Indeed, patients with sarcoidosis 
are up to 11 times more likely to develop lymphoma as compared to the general population8. 
Specifically, an increased risk of Hodgkin lymphoma was observed in patients with sarcoidosis in a 
population-based case-control study in Scandinavia4. In the majority of cases, lymphoma occurred 





























































after sarcoidosis, usually within a short time interval9. Patients with sarcoidosis-lymphoma 
syndrome tend to be significantly older than unselected individuals with sarcoidosis10. In contrast, 
in our study, no differences were observed in the median age of patients with or without lymphoma. 
Different genetic background or environmental exposures may account for this inconsistent 
finding1. Similar to our study, Blank and colleagues11 performed a retrospective study analyzing the 
incidence and type of malignancies in a large cohort of patients with sarcoidosis, showing a similar 
rate of lymphoproliferative disorders (4.1% vs 4.8 % in our study), thus confirming the 
generalizability of our findings.
In our study, a number of limitations should also be acknowledged, the main being the small 
number of patients with sarcoidosis-lymphoma syndrome, although, reassuringly, a comparable 
prevalence of sarcoidosis-lymphoma syndrome was found in previous similar studies11. Moreover, 
the retrospective design is prone to incomplete or missing data. Finally, the lack of a control 
population without sarcoidosis followed over the same period of time precludes us from identifying 
sarcoidosis as a risk factor for malignancy. These limitations notwithstanding, our data suggest that 
in patients with sarcoidosis persistently elevated serum ACE levels should raise the suspicion of 
supervening lymphoma. ACE is generally used to monitor disease behaviour during follow-up1. Thus, 
we argue that serum ACE levels may reflect the intensity of the lymphocytic activation occurring in 
patients with sarcoidosis, and that an exuberant and uncontrolled lymphocytic activation, perhaps 
not counterbalanced by T-regulatory cell activity12, may trigger the development of lymphoma. In 
support of our hypothesis, evidence suggests that serum ACE is lower in patients with lymphoma 
alone13. Interestingly, we also observed that the CD4/CD8 lymphocyte ratio in bronco-alveolar 
lavage was higher among patients with sarcoidosis-lymphoma syndrome (data not shown), further 
supporting the hypothesis of an aberrant lymphocytic activation (T-helper) in patients with both 
conditions.
In conclusion, our study suggests the existence of clinical, radiological and serological 
differences in sarcoidosis with or without lymphoma syndrome. Larger prospective studies are 
required to confirm and expand on these observations.
We acknowledge that this research was partially supported by the Italian Ministry of University and 
Research (MIUR) - Department of Excellence project PREMIA (PREcision MedIcine Approach: 
bringing biomarker research  to clinic)  





























































Table 1. Demographic and clinical characteristics of the study population
Sarcoidosis Sarcoidosis + Lymphoma P
Patients, n 199 10










             No
             Ex








FVC, litres 3.3 (± 1,1) 4.2 (± 0,8) 0.052
FVC, % predicted 96.2 (± 18.0) 100.1 (± 19,2) 0.583
FEV1, litres 2.7 (± 0,9) 3.3 (± 0,6) 0.92
FEV1, % predicted 94.4 (± 19,1) 97.1 (± 18.0) 0.720
DLCO, ml min kPa 6.2 (± 2,6) 7.4 (± 1,8) 0.234
DLCO, % predicted 73.9 (± 23,8) 75.3 (± 15,3) 0.881
Chest X-rays stage (%)
Stage 0 15 (7.5) 0 (0)
Stage 1 59 (29.7) 5 (50)
Stage II 89 (44.7) 3 (30) 0.671
Stage III 30 (15.1) 2 (20)
Stage IV 6 (3.0) 0 (0)
ACE (U/L)
At diagnosis 55.1 (± 36,7) 94.9 (± 43,9) 0.02
First relapse 86.0 (± 56,4) - N/A
Last follow up 50.7 (± 41,7) 83.3 (± 42,5) 0.04
Relapses 36 (18.9%) 0 (0%) N/A
Organ involvement
Mediastinum 159 (79.9) 8 (80) 0.994
Lungs 137 (68.8) 7 (70) 0.939
Skin 53 (26.6) 4 (40) 0.354
Lymph-nodes 34 (17.6) 3 (30) 0.321
Eyes 12 (6.0) 1 (10) 0.612
Spleen 12 (6.0) 1 (10) 0.612
Liver 17 (8.5) 0 (0) 0.335
Salivary glands 5 (2.5) 0 (0) 0.999
Nervous system 7 (3.5) 0 (0) 0.999
Hypercalcemia 1 (0.5) 0 (0) 0.999
Bones 2 (1.0) 1 (10) 0.137
ORL 1 (0.5) 0 (0) 0.999
Gastrointestinal 2 (1.0) 0 (0) 0.999
Lacrimal glands 1 (0.5) 1 (10) 0.094
Bone marrow 2 (1.0) 0 (0) 0.999
Heart 1 (0.5) 0 (0) 0.999
Testis 1 (0.5) 0 (0) 0.999





























































Continuous variables are expressed as mean±SD if normally distributed, as median (min, max) if non-normally distributed; 
categorical variables are expressed as absolute numbers and percentages
N/A = not applicable
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Methods
Study design: present key elements of study design early in the paper (see row 10)
Setting: describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection (from row 11 to row 13)
Participants
(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe 
methods of follow-up (from row 14 to row 18)
(b) For matched studies, give matching criteria and number of exposed and unexposed (not 
applicable)
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modifiers. Give diagnostic criteria, if applicable (from row 14 to row 18)
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2 statisticians co-authored this “research letter”. They therefore decided the most appropriate 
statistics to apply to this study
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a) Report numbers of individuals at each stage of study - eg numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (from 
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study, we included all patients with a diagnosis of sarcoidosis with or without lymphoma)
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exposures and potential confounders (from row 15 to row 18)
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Main results
a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision 
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c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time 
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Discussion
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Interpretation. Give a cautious overall interpretation of results considering objectives, limitations, 
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Modena, 24th December 2018
Dear Editor, Dear Prof. Martin Kolb
European Respiratory Journal
The association between sarcoidosis and lymphoma is well established. Indeed, patients with 
sarcoidosis are up to 11 times more likely to develop lymphoma as compared to the general population. 
However, the distinctive clinical features of patients with sarcoidosis and lymphoma, and the 
mechanism underlying this association are still unclear. 
Including 209 patients, in this manuscript, that we would like to propose as "research letter”, we 
retrospectively reviewed differences in sarcoidosis patients with and without lymphoma, showing 
clinical, radiological and serological differences, including lung function and chest X ray presentation. 
Furthermore, serum angiotensin-converting enzyme (ACE) levels resulted significantly higher in patients 
with sarcoidosis-lymphoma syndrome both at the time of the diagnosis and at the last follow-up 
measurement available, indicating that those patients with persistently elevated serum ACE levels 
should be carefully monitored over longer periods, despite the similar outcomes in term of mortality 
between the two groups.
To our knowledge, this is the first observation showing the existence of clinical, radiological and 
serological differences in sarcoidosis with or without lymphoma syndrome.
The material included in this manuscript is original, is not being considered for publication 
elsewhere, including publicly accessible websites or e-print servers, no part of the research presented 
has been funded by tobacco industry sources, and all authors have read the manuscript and approve its 
submission. Finally, the Authors do not have any competing financial interest.
We hope you will consider our manuscript for publication in the Journal.
Thank you very much indeed for your interest in our work.
Looking forward to hearing from you.
Yours sincerely,
Fabrizio Luppi (for the Authors)
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